Previous 10 | Next 10 |
CLEVELAND, May 20, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq: ATHX) announced additional favorable data from its exploratory Phase 1/2 acute respiratory distress syndrome (ARDS) clinical trial. Dr. Geoff Bellingan, Medical Director at University College London Hospitals, described the...
Introduction: The forgotten promises of stem cell research Since the discovery of stem cells, researchers have shown high ambitions in plans and projects to ensure better human health. And indeed, stem cells - which are basically universal human building blocks - can be a solution to many ex...
The FDA designates Athersys' (NASDAQ: ATHX ) MultiStem cell therapy for Fast Track review for the treatment of acute respiratory distress syndrome (ARDS). More news on: Athersys, Inc., Healthcare stocks news, Stocks on the move, Read more ...
CLEVELAND, May 14, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq: ATHX) announced today that its clinical program evaluating MultiStem® cell therapy for the treatment of Acute Respiratory Distress Syndrome (“ARDS”) has received Fast Track designation from the United Sta...
Athersys ( ATHX ) is a developer of regenerative medicines with its lead drug candidate, a MultiStem cell therapy, targeting ischemic stroke in a late-stage study. MultiStem has a Fast Track and RMAT (Regenerative Medicines Advanced Therapy) designation in the USA, both of which provide for ex...
Athersys, Inc. (ATHX) Q1 2019 Results Conference Call May 08, 2019 04:30 PM ET Company Participants Karen Hunady - Director, Corporate Communications and IR BJ Lehmann - President and COO Laura Campbell - SVP, Finance Conference Call Participants Gil Blum - Needham & Co...
Athersys (NASDAQ: ATHX ): Q1 GAAP EPS of -$0.09 misses by $0.01 . Revenue of $1.5M (+36.4% Y/Y) misses by $0.32M . Press Release More news on: Athersys, Inc., Earnings news and commentary, Healthcare stocks news, ,
CLEVELAND, May 08, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended March 31, 2019. Highlights of the first quarter of 2019 and recent events include: Announced positive results from our exploratory clinical s...
NEW YORK, NY / ACCESSWIRE / May 6, 2019 / In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Enbridge Inc (NYSE:ENB), Quest Diagnostics Incorporated (NYSE: DGX), Sea Limited ...
Arrowhead Pharmaceuticals ( ARWR ) - The company announced that dosing has begun in a new triple combination cohort utilizing JNJ-3989 plus additional undisclosed agents in the ongoing phase 1/2 study in patients with chronic hepatitis B virus. As a result of opening this new cohort, Arrowhe...
News, Short Squeeze, Breakout and More Instantly...
Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to ra...